Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Moregard dominates Macao final against Calderano to clinch second WTT Champions title
19+ hour, 20+ min ago (84+ words) news.com.au Moregard dominates Macao final against Calderano to clinch second WTT Champions title Australian Olympians have slammed US actor Sydney Sweeney’s provocative new ad, accusing it of setting women’s sport backwards. Sydney Sweeney has sparked backlash after stripping…...
Aeliana’s racing path for 2026 to be decided by draw
1+ day, 9+ hour ago (372+ words) Chris Waller is contemplating whether to pit his mare Aeliana against stablemate Autumn Glow in the 7 Stakes at Randwick or send her to Melbourne for a Group 1 contest at Caulfield. The decision is anticipated later this week. Aeliana is set…...
Lorenzo Di Vara Drops Darryl Verdonk, Wins K-1 World Max Opener By Decision - Highlights
2+ day, 1+ hour ago (21+ words) Lorenzo Di Vara dropped Darryl Verdonk in Round 2 and won a unanimous decision at K-1 World Max 2026 in Tokyo....
TNXP: Strong sales growth, pipeline progress, and robust cash position drive optimism for future milestones
3+ day, 16+ hour ago (79+ words) tradingview.com TONMYA's launch for fibromyalgia has shown strong early sales growth and broadening access, with a unique mechanism and favorable tolerability. The pipeline includes a phase II-ready Lyme disease antibody and an anti-CD40 ligand program for transplantation, supported by…...
Insightec spinout Lotus Neuro launches brain drug delivery platform
4+ day, 3+ hour ago (235+ words) Lotus Neuro, a clinical-stage biotechnology company spun out of focused ultrasound specialist Insightec, launched publicly with a platform designed to improve delivery of therapeutics across the blood-brain barrier (BBB). The underlying Insightec technology has already been evaluated clinically in several…...
NAMS: PREVAIL’s interim analysis and upcoming RUBIN data position obicetrapib for a differentiated launch
4+ day, 15+ hour ago (86+ words) TradingView NAMS: PREVAIL’s interim analysis and upcoming RUBIN data position obicetrapib for a differentiated launch Obicetrapib, a differentiated CETP inhibitor, is nearing key readouts from the PREVAIL cardiovascular outcomes trial and RUBIN diabetes study, with plans for launch in 12–18 months....
Prescient Therapeutics: what has changed since the last PTX100 CTCL update
5+ day, 22+ hour ago (173+ words) Small Caps speaks with Prescient Therapeutics (ASX: PTX) for a general company update focused on what has changed since our last interview on PTX100 in cutaneous T-cell lymphoma (CTCL). Management discusses the most important recent developments, what has or has not…...
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines
5+ day, 17+ hour ago (142+ words) TradingView Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines Adicet Bio posted a September 2026 investor presentation highlighting prula-cel clinical progress and IND-cleared ADI-212 with near-term clinic timelines. - Posted investor presentation on Sept 8, 2026; furnished as Exhibit 99.1 under…...
TABLE-Nadex -Q1 group results — TradingView News
6+ day, 6+ hour ago (9+ words) TABLE-Nadex -Q1 group results TradingView TABLE-Nadex -Q1 group results...
Revenio Group: Visionix integration advances, synergies materialize, and 2026 guidance targets strong sales growth
5+ day, 22+ hour ago (84+ words) TradingView Revenio Group: Visionix integration advances, synergies materialize, and 2026 guidance targets strong sales growth Integration of Visionix is ahead of plan, with EUR 5 million in synergies realized and flat H1 performance as expected. Q2 net sales rose 48.1% due to the acquisition, but…...